News >

High Response Rate in Histiocytic Disease With MEK Inhibition

Gina Columbus @ginacolumbusonc
Published: Wednesday, Jan 03, 2018

Eli Diamond, MD

Eli Diamond, MD
The MEK inhibitor cobimetinib (Cotellic) led to objective responses in 14 of 16 patients with BRAF-mutated and wild-type histiocytic disorders, according to results of a phase II trial presented at the 2017 ASH Annual Meeting.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication